Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares. With the shares off about 30% since the surprising news of an ...

On Wednesday, TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 from the previous $1,230. Despite the reduction, the firm ...

Truist lowered the firm’s price target on Regeneron (REGN) to $1,126 from $1,137 and keeps a Buy rating on the shares after its Q3 results. Investor focus has been on Eylea and Eylea HD ...

On Wednesday, Truist Securities revised its price target for Regeneron Pharmaceuticals stock, traded on (NASDAQ: REGN), lowering it to $975 from the previous target of $1,004.Despite the reduction ...

Barclays lowered the firm’s price target on Regeneron (REGN) to $1,065 from $1,080 and keeps an Overweight rating on the shares post the Q3 report. The firm says recent pressure on Regeneron ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Citigroup cut their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th.

On Wednesday, RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ: REGN), reducing it to $1,045 from the previous target of $1,059.Despite the decrease, the firm ...

Citi lowered the firm’s price target on Regeneron (REGN) to $750 from $795 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,184 from $1,215 and keeps an Outperform rating on the shares as part of a ...